Eikon Therapeutics Files for IPO Amid Biotech Rally Test
Eikon Therapeutics, a cancer-focused biotech led by former Merck executives including Roger Perlmutter, filed for a US IPO on January 9, 2026, to list on Nasdaq under ticker EIKN.1234
The company has raised over $1 billion in private funding since 2019 and plans to use IPO proceeds to advance its pipeline, including EIK1001 (TLR7/8 dual agonist in Phase 2/3 for melanoma and NSCLC), EIK1003, and other oncology assets.123
Eikon's filing follows Aktis Oncology's $318 million IPO and signals a potential biotech IPO rebound after a slow 2025, with estimates suggesting Eikon could raise up to $300 million.123
Underwriters include J.P. Morgan, Morgan Stanley, BofA Securities, and Cantor Fitzgerald; the company was backed by investors like Sergey Brin's Catalyst4.2347
Eikon originated from Nobel Prize-winning protein imaging technology but built its pipeline through in-licensing deals.2
Sources:
1. https://www.biospace.com/business/veradermics-eikon-eye-public-market-debut-as-ipo-tap-opens
2. https://www.biopharmadive.com/news/eikon-ipo-file-cancer-tlr-parp-roger-perlmutter/809308/
3. https://www.renaissancecapital.com/IPO-Center/News/116076/Immuno-responsive-cancer-biotech-Eikon-Therapeutics-files-for-an-estimated-
4. https://whbl.com/2026/01/09/biopharmaceutical-firm-eikon-therapeutics-files-for-us-ipo/
7. https://www.axios.com/pro/health-tech-deals/2026/01/12/sergey-brin-catalyst4-eikon-ipo-parkinsons